NFE2L2, nuclear factor, erythroid 2 like 2, 4780

N. diseases: 823; N. variants: 34
Disease: Fatty Liver ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.400 Biomarker disease BEFREE Niga-ichigoside F1 ameliorates high-fat diet-induced hepatic steatosis in male mice by Nrf2 activation. 29309075 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.400 Biomarker disease BEFREE HFD-induced liver steatosis (i) was reduced by 32% by EPA, without changes in oxidative stress-related parameters and mild recovery of Nrf2 functioning affording antioxidation and (ii) was decreased by 42% by HT, concomitantly with total regain of the glutathione status diminished by HFD, 42% to 59% recovery of lipid peroxidation and protein oxidation enhanced by HFD, and regain of Nrf2 functioning, whereas (iii) combined EPA + HT supplementation elicited 74% reduction in liver steatosis, with total recovery of the antioxidant potential in a similar manner than HT. 30057681 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.400 Biomarker disease CTD_human High Fat Diet-Induced Hepatic 18-Carbon Fatty Acids Accumulation Up-Regulates CYP2A5/CYP2A6 via NF-E2-Related Factor 2. 28555106 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.400 GeneticVariation disease BEFREE HFD + RM mice had 40% less hepatic steatosis (<i>P</i> < 0.05) and lower upregulation of PPAR-α (33%), ACOX1 (50%), NRF2 (39%), and HO-1 (68%) protein concentrations than did the HFD mice (<i>P</i> < 0.05).<b>Conclusions:</b> Our findings suggest that RM supplementation prevents the obese phenotype observed in HFD-fed mice by downregulating inflammatory cytokine expression and secretion and stimulating hepatic antioxidant and fatty acid oxidation markers. 28298541 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.400 AlteredExpression disease BEFREE HFD-fed mice exhibited (i) liver steatosis; (ii) inflammation; (iii) oxidative stress; and (iv) depletion of n-3 LCPUFAs, together with down-regulation of PPAR-α and Nrf2, and up-regulation of NF-κB. 28386616 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.400 Biomarker disease BEFREE Nrf2 Activation Is Required for Ligustrazine to Inhibit Hepatic Steatosis in Alcohol-Preferring Mice and Hepatocytes. 27837167 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.400 Biomarker disease BEFREE In summary, DMY likely modulates p62 and autophagy crosstalk with the Keap-1/Nrf2 pathway to alleviate liver steatosis and the inflammatory response in the pathological progression of ALD. 28419832 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.400 Biomarker disease BEFREE We review relevant evidence in the literature that these two mechanisms may contribute to the protective role of Nrf2 in the development of hepatic steatosis and in the progression to steatohepatitis, particularly in young animals. 26120584 2015
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.400 AlteredExpression disease BEFREE Additionally, curcumin induced the expression of Nrf2 and FXR in liver, strongly implying close relationship between inhibitory effect of curcumin on hepatic steatosis and the above two genes. 26305715 2015
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.400 Biomarker disease BEFREE Supplementation of N-acetylcysteine alleviates fatty liver and liver injury induced by chronic alcohol exposure, which is associated with suppressed Nrf2 activation and attenuated VLDLR increase in the liver. 24170703 2014
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.400 Biomarker disease BEFREE A deficiency of Nrf2 enhanced the ability of LXRα agonist to promote hepatic steatosis, as mediated by lipogenic gene induction. 21504366 2011
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.400 AlteredExpression disease BEFREE Our results demonstrate that LQ has an efficacy to activate Nrf2, which contributes to inhibiting the activity of LXRα that leads to SREBP-1c induction and hepatic steatosis. 20677908 2011